Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Human TAK1 Synthetic Peptide
Shop All Thermo Scientific Products
Click to view available options
:
50μg
Description
TAK1 Synthetic Peptide, PEP-0201, from Invitrogen.
TAK1 (also known as MAP3K7), a part of the serine/threonine kinase family, is a versatile protein with many signaling functions. Originally identified as a TGF- beta-activated kinase, TAK1 interacts with TGF- beta-receptor and TRAF6 to modulate TGF- beta activation of JNK and p38. It has additional roles in activation of p38 and JNK through Wnt, BMP, and activin signaling pathways as well in response to thyroid hormone, osmotic stress, endothelin, and ephrine. Through activation of von Hippel-Lindau tumor suppressor expression, TAK1 represses PDGF-B, integrin beta1 and integrin beta5, promoting proper wound healing. TAK1 also plays an essential role in IKK activation in numerous signaling pathways including IL-1, IL-6, IL-18, TNF, CD40, TLR, and RIG-I. Activation of the TAK1-IKK pathway requires TAB2/3 and ubiquitination. In this process, TAB2/3 binds to the C-terminal region of TAK1 and becomes polyubiquitinated, TAK1 is autophosphorylated at Thr178, Thr184, Thr187 and Ser192, and finally TAK1 phosphorylates IKK- beta. Additionally, TAK1 represses human telomerase reverse transcriptase suggesting a role in regulation of cell lifespan. This peptide corresponds to 14 amino acids near the amino terminus of human TAK1 (NT).PEP-0201 can be used as a blocking peptide with polyclonal antibody PA5-20083.
Specifications
Specifications
Gene ID (Entrez) | 6885 |
Species | Human |
Purification Method | purified |
Accession Number | O43318 |
Common Name | Human TAK1 |
Concentration | 200 μg/mL |
Content And Storage | -20°C |
Description | Synthetic Peptide |
Format | Liquid |
Formulation | PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2 |
Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction